AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension

Active, not recruiting · Phase 1, Phase 2 · NCT04499248

Conditions: Open-angle Glaucoma, Ocular Hypertension

Research payments reported, 2025: $861,717
U.S. investigators named: 29
Sites paid: 39
Planned or actual enrollment: 100

About the trial

Sponsor: AbbVie
Tested: AGN-193408 SR (drug), Lumigan (other), Sham Administration (other), Lumigan Vehicle (other), AGN-193408 SR (drug), Sham Administration (other), Lumigan Vehicle (other)
Dates: Started 2020-11-16; completion 2029-04
Results posted: Not yet

This is a multicenter, open-label, dose escalation (Cohort 1) to masked, randomized, parallel-groups (Cohort 2) and (Cohort 3) study to evaluate the safety and efficacy of AGN-193408 SR in participants with open-angle glaucoma or ocular hypertension

From ClinicalTrials.gov, last updated 2026-05-22. Full record, eligibility and contacts (opens in a new tab)

Industry funding

AbbVie Inc. reported $861,717 in research payments for this study in 2025 (155 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.

At a glance

About the trial

Industry funding

U.S. investigators named on this study

Sites paid to run it